Abstracts tagged "Lupus"

Abstract Number: 2863 • 2016 ACR/ARHP Annual Meeting
High Frequency of Terminally Differentiated CD8+ T Cells Characterize Systemic Lupus Erythematosus Patients with Renal Involvement
Nataly Manjarrez-Orduño¹, Laurence Menard¹, Julie Carman¹, Suzanne Suchard¹, Francesca Casano¹, Deborah Lee¹, Sium Habte¹, Sherif Daouti², Selena Kansal³, Dana Banas³, Can Jiang³, Dawn Stetsko³, Mark Cunningham³, Vivek Jayaswal⁴, Somnath Bandyopadhyay³, Sarah Hu³, Richard A. Furie⁵ and Steven G. Nadler⁶, ¹Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Princeton, NY, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Biocon Bristol-Myers Squibb Research Center, Bangalore, India, ⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ⁶Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: SLE is a highly heterogeneous disease. The identification of disease subtypes with different pathological mechanisms is crucial to identify subjects with different disease progression…
Abstract Number: 743 • 2016 ACR/ARHP Annual Meeting
Long-Term Hydroxychloroquine Therapy and Low-Dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Serena Fasano¹, Michele Iudici², Ilenia Pantano³, Luciana Pierro³ and Gabriele Valentini⁴, ¹Internal and Experimental Medicine Naples, Italy, Rheumatology Unit, Second University of Naples, Naples, Italy, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Rheumatology Unit, Second University of Naples, Naples, Italy, ⁴Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy
Background/Purpose: Hydroxychloroquine (HCQ) is a mainstay of treatment in patients with SLE. It has been demonstrated to reduce disease activity and prevent damage accrual and…
Abstract Number: 1186 • 2016 ACR/ARHP Annual Meeting
The Use of Clinical Mucosal Manifestations to Differentiate Patients with Lupus and Dermatomyositis: Transversal, Retrospective and Analytical Study of 116 Patients
Cristián Vera-Kellet Sr., Pablo del Barrio-Díaz Sr., Jorge Manríquez-Moreno Sr. and Carlos Reyes-Vivanco Sr., Dermatology, Pontificia Universidad Católica de Chile, Santiago, Chile
Background/Purpose: There are few studies comparing oral manifestations in patients with Cutaneous Lupus (CL), Systemic Lupus Erythematosus (SLE) and Dermatomyositis (DM). Our objective was to…
Abstract Number: 1839 • 2016 ACR/ARHP Annual Meeting
Elevated Plasma Cell-Free Mitochondrial DNA Defines a Subgroup of Lupus Patients with Membranous Lupus Nephritis
David Fernandez¹, Maria A. Pabon², Mikhail Olferiev¹, Ana C. Hernandez², Faryal Malick², Leila Khalili¹, Augustine M. K. Choi², Kiichi Nakahira² and Mary K. Crow¹, ¹Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with protean manifestations, characterized by production of antibodies against nucleic acids and upregulation of type I…
Abstract Number: 2866 • 2016 ACR/ARHP Annual Meeting
Lupus HDL Induces Pro-Inflammatory Responses in Macrophages By Binding LOX1Rand Failing to Promote ATF3 Activity
Carolyne K. Smith¹, Nickie Seto¹, Anuradha Vivekanandan-Giri², Wenmin Yuan³, Martin Playford⁴, Zerai G. Manna⁵, Sarfaraz A. Hasni⁶, Rui Kuai³, Nehal N. Mehta⁴, Anna Schwendeman³, Subramaniam Pennathur² and Mariana Kaplan⁷, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Internal Medicine/Nephrology, University of Michigan Nephrology, Ann Arbor, MI, ³Department of Medicinal Chemistry and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, ⁴NHLBI, National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶Lupus Clinical Research Program, Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ⁷NIAMS/NIH, Bethesda, MD
Background/Purpose: Recent evidence indicates that high-density lipoprotein (HDL) exerts vasculoprotective activities by promoting activating transcription factor 3 (ATF3), leading to down-regulation of TLR-induced inflammatory responses.…
Abstract Number: 772 • 2016 ACR/ARHP Annual Meeting
Effect of HMG-CoA Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Givenchy Maree Garcia, Annalyn Urbano and Evelyn Salido, Section of Rheumatology, University of the Philippines - Philippine General Hospital, Manila, Philippines
Background/Purpose: Statins have been shown to have anti-inflammatory and immunomodulatory effects. In vitro studies show that these drugs inhibit inflammatory cells, decrease the expression of…
Abstract Number: 1250 • 2016 ACR/ARHP Annual Meeting
Mortality in Indigenous Populations of Canada, the United States, Australia, and New Zealand with Rheumatic Disease: A Systematic Review
Kelle Hurd¹ and Cheryl Barnabe², ¹University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Indigenous populations of Canada, America, Australia, and New Zealand share similar experiences of colonization impacting their rheumatic disease clinical outcomes. The objective of our…
Abstract Number: 1970 • 2016 ACR/ARHP Annual Meeting
Disparities in Access to Specialist Care at the Time of Diagnosis of Systemic Lupus Erythematosus
Lisa Gaynon¹, Patricia P. Katz², Maria Dall'Era³, Laura Trupin², Lindsey A. Criswell⁴, Cristina Lanata⁴, Charles Hemlick⁵ and Jinoos Yazdany², ¹Internal Medicine, California Pacific Medical Center, San Francisco, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Division of Rheumatology, UCSF, San Francisco, CA, ⁵Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Disparities in outcomes among racial/ethnic minorities and individuals with low socioeconomic status with systemic lupus erythematosus (SLE) have been well reported. The degree to…
Abstract Number: 2873 • 2016 ACR/ARHP Annual Meeting
B-Cell activating Factor Genetic Variants in Systemic Lupus Erythematosus and Lupus Related Atherosclerosis
Evangelos Theodorou¹, Adrianos Nezos², Pinelopi Kostantopoulou³, Maria Tektonidou⁴, Michael Koutsilieris⁵ and Clio P. Mavragani⁵, ¹Rheumatology, 251 Hellenic (Greek) Air Force Hospital, Athens, Greece, ²Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, ³Rheumatology Department, General Hospital of Athens "G.Gennimatas", Αthens, Greece, ⁴Laikon Hospital, Athens University Medical School, Athens, Greece, ⁵Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease with an increased atherosclerotic risk compared to healthy population, partially explained by traditional cardiovascular…
Abstract Number: 965 • 2016 ACR/ARHP Annual Meeting
Clinical and Serologic Variables Associated with Renal Response Among Lupus Nephritis Phase III Trial Patients Treated with Standard of Care Immunosuppression
Matthew D. Cascino¹, Peter Lambert², Anna Decker², Tamiko Katsumoto², Jay Garg², Paul Brunetta², Maria Dall'Era¹ and Leonard L. Dragone², ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Genentech, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is associated with high treatment failure rates and the development of new therapies for LN is limited by the lack of…
Abstract Number: 1362 • 2016 ACR/ARHP Annual Meeting
Associations Between 25-Hydroxyvitamin D, Parathyroid Hormone, and Cathelicidin Concentrations with Inflammation and Cardiovascular Risk in Subjects with Pediatric Systemic Lupus Erythematosus
Varsha Gupta¹, Vin Tangpricha², Eric Yow³, Grace McComsey⁴, Laura E. Schanberg⁵, Angela B. Robinson⁶ and APPLE Investigators Group, ¹Case Western Reserve University School of Medicine, Cleveland, OH, ²Medicine, Emory University School of Medicine, Atlanta, GA, ³Biostatistics, Duke Clinical Research Institute, Durham, NC, ⁴Pediatric Infectious Diseases, Rheumatology, and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ⁵Department of Pediatrics, Duke University Medical Center, Durham, NC, ⁶Pediatric Rheumatology, Rainbow Babies and Childrens Hospital, Cleveland, OH
Background/Purpose: Previous studies have shown associations between reduced serum 25-hydroxyvitamin D (25OHD) levels, inflammation, and disease activity in pediatric systemic lupus erythematosus (pSLE). The goal…
Abstract Number: 1971 • 2016 ACR/ARHP Annual Meeting
Predictors of Delays to Care and Associated Outcomes in Pediatric Lupus Patients from the Childhood Arthritis and Rheumatology Research Alliance Registry
Tamar Rubinstein^1,2, Norman Ilowite^3,4 and Dawn Wahezi^5,6, ¹Division of Pediatric Rheumatology, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Division of Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁴Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁵Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁶Pediatric Rheumatology, The Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: CARRA registry data for participants meeting ACR classification criteria for lupus were analyzed. Delays of one month, 3 months, and one year from symptom…
Abstract Number: 2885 • 2016 ACR/ARHP Annual Meeting
Expression Levels and Function of the Inhibitory Molecule, Immunoglobulin like Transcript 7 (ILT7), Are Decreased on Circulating Plasmacytoid Dendritic Cells in SLE Patients with High ANA Titers
Mark A. Jensen¹, Jessica M. Dorschner², Danielle Vsetecka², Shreyasee Amin³, Ashima Makol³, Floranne C. Ernste⁴, Thomas Osborn³, Kevin Moder³, Vaidehi Chowdhary³ and Timothy B. Niewold⁵, ¹Department of Immunology and Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁵Rheumatology and Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disease often involving multiple organs. In SLE, immune complexes containing autoreactive antibody and nuclear material activate…
Abstract Number: 741 • 2015 ACR/ARHP Annual Meeting
Satisfaction and Impact Associated with the Addition of Belimumab to Systemic Lupus Erythematosus (SLE) Treatment: A Cross-Sectional Survey of US Rheumatologists and Their Patients
Katie Pascoe¹, Steve Lobosco², David Bell³, Ben Hoskin³, Sulabha Ramachandran⁴, Bonnie Pobiner⁵ and David Chang⁶, ¹Value Evidence and Outcomes, GlaxoSmithKline, Uxbridge, United Kingdom, ²Adelphi Real World Ltd., Macclesfield, United Kingdom, ³Autoimmune, Adelphi Real World Ltd., Manchester, United Kingdom, ⁴Value Evidence and Outcomes, GlaxoSmithKline, Renaissance Centre, PA, ⁵Immuno-Inflammation Therapy Area, GlaxoSmithKline, Triangle Park, NC, ⁶US Medical Affairs, GlaxoSmithKline, Philadelphia, PA
Background/Purpose: Patient and physician treatment satisfaction influences long-term adherence with a treatment regimen. The primary objective was to identify factors linked to satisfaction with the…
Abstract Number: 987 • 2015 ACR/ARHP Annual Meeting
Pre-Emptive Renal Transplantation Among End Stage Renal Disease Patients with and without SLE
Anna R. Broder¹, Wenzhu Mowrey², Ladan Golestaneh³, Mimi Kim⁴, Karen H. Costenbader⁵ and Chaim Putterman⁶, ¹Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Department of Epidemiology and Population Health/Division of Biostatistics, Albert Einstein College of Medicine, Bronx, NY, ³Medicine/Nephrology, Albert Einstein College of Medicine, Bronx, NY, ⁴Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁵Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lack of evidence-based recommendations about pre-emptive renal transplantation in systemic lupus erythematosus (SLE) patients with end stage renal disease (ESRD) may be unnecessarily delaying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].